Candel Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Candel Therapeutics, Inc. carries a market capitalization of 846.27M, placing it among publicly traded companies globally. Its enterprise value stands at 631.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 846.27M |
| Enterprise Value | 631.97M |
Share Statistics
Candel Therapeutics, Inc. currently has 76.12M shares outstanding.
| Shares Outstanding | 76.12M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 6.22 |
| P/TBV Ratio | 6.22 |
| P/FCF Ratio | -11.59 |
| P/OCF Ratio | -11.32 |
Financial Position
Candel Therapeutics, Inc. maintains a current ratio of 16.09, meaning it holds 16.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.26, indicating elevated leverage, while an interest coverage ratio of -15.09 demonstrates limited ability to service its debt obligations.
| Current Ratio | 16.09 |
| Quick Ratio | 15.89 |
| Debt / Equity | 39.26 |
| Debt / EBITDA | -0.70 |
| Interest Coverage | -15.09 |
Financial Efficiency
| Return on Equity (ROE) | -81.84 |
| Return on Assets (ROA) | -56.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Candel Therapeutics, Inc.'s stock has gained approximately 112.70718% over the past 52 weeks. The 50-day moving average sits at 11.31, while the 200-day moving average is 7.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | 112.70718% |
| 50-Day Moving Average | 11.31 |
| 200-Day Moving Average | 7.79 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -71.18M, while operating income came in at -71.86M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -71.86M |
| Pretax Income | -88.53M |
| Net Income | -88.53M |
| EBITDA | -71.18M |
| EBIT | -71.86M |
| Earnings Per Share (EPS) | -1.44 |
Balance Sheet
Candel Therapeutics, Inc. holds 201.57M in cash and equivalents against 49.52M in total debt, resulting in a net debt position of -153.73M. Total book value stands at 126.13M, with working capital of 191.47M providing operational flexibility.
| Cash & Cash Equivalents | 201.57M |
| Total Debt | 49.52M |
| Net Debt | -153.73M |
| Equity (Book Value) | 126.13M |
| Book Value Per Share | 1.66 |
| Working Capital | 191.47M |
Cash Flow
Candel Therapeutics, Inc. produced -56.02M in operating cash flow over the past twelve months. After subtracting -1.30M in capital expenditures, free cash flow totaled -57.32M - equivalent to -0.93 per share.
| Operating Cash Flow | -56.02M |
| Capital Expenditures | -1.30M |
| Free Cash Flow | -57.32M |
| FCF Per Share | -0.93 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -20.19 |
| FCF Yield | -8.63 |
Scores
Candel Therapeutics, Inc. posts an Altman Z-Score of 3.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.83 |